Menu
News
- All
- Nirogy News
- Press Releases
- All
- Nirogy News
- Press Releases
Nirogy Therapeutics to Present at AACR Annual Meeting 2021
E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells …
Market ‘Solutes’ Nirogy Small-Molecule Flag with $16.5M Series A
Boston-based Nirogy Therapeutics Inc.’s $16.5 million series A round is meant to enable a pipeline of small-molecule drugs targeting the solute carrier family of transporter …
Nirogy Therapeutics Emerges with $16.5M to Target Metabolite Transporters
Over the next year, Nirogy will narrow its lactate transporter inhibitor candidates down to one for preclinical development and IND-enabling studies. (Getty/EPlus/asonfang) After years working …
Nirogy Raises $16.5 Million to Focus on Transporter Proteins
Nirogy Therapeutics, based in Boston, launched with a $16.5 million Series A financing round. The round was co-led by Santé Ventures and Sporos. Nirogy is …
Nirogy Therapeutics Launches with $16.5 Million Series A Financing
Proceeds to support the development of small-molecule drugs that modulate the transport of metabolites for oncology and immunology indications Boston, January 26, 2021 – Nirogy …
Nirogy Therapeutics is Awarded $2 Million NIH/NCI SBIR Grant to Develop dMCTi for TNBC
Nirogy Therapeutics Inc. today announced that it was awarded a $2M NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast …
